Noah Medical Takes a Step Forward in Fighting Lung Cancer
In the battle against lung cancer, US company Noah Medical has made a significant stride. The results of their study on the accuracy of the surgical robotic platform Galaxy were positive. The system provides reliable visualization data and allows for diagnostic and therapeutic interventions in the airways of patients with lung cancer.
According to Noah Medical, the Galaxy system employs advanced imaging techniques such as tomosynthesis and fluoroscopy. These imaging techniques help to display the location of potentially cancerous lesions in real-time, which can then be treated.
Using a multi-axis robot, the system can control a catheter inside the human body to remove any lesions. In clinical trials, the technique known as Tool in Lesion (TiLT) achieved a 100 percent success rate in navigating to lesions. Additionally, a diagnostic yield of 100 percent was also achieved with a TiLT accuracy of 95 percent.
The Galaxy system received FDA approval in March 2023, and a first human trial is currently taking place in Australia. To bring the system into clinics, Noah Medical raised 150 million dollars in early April from investors.
With the ability to provide accurate and reliable data for lung cancer patients and the potential to remove lesions via a robotic platform, the Galaxy system could represent a significant breakthrough in cancer treatment.
